- Home
- VKTX vs RNA Comparison
VKTX vs RNA Comparison
Compare VKTX & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- RNA
- Stock Information
- Founded
- VKTX 2012
- RNA 2012
- Country
- VKTX United States
- RNA United States
- Employees
- VKTX N/A
- RNA N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- RNA Health Care
- Exchange
- VKTX Nasdaq
- RNA Nasdaq
- Market Cap
- VKTX 3.5B
- RNA 4.0B
- IPO Year
- VKTX 2015
- RNA 2020
- Fundamental
- Price
- VKTX $34.42
- RNA $36.27
- Analyst Decision
- VKTX Strong Buy
- RNA Strong Buy
- Analyst Count
- VKTX 13
- RNA 14
- Target Price
- VKTX $86.92
- RNA $67.71
- AVG Volume (30 Days)
- VKTX 4.1M
- RNA 2.4M
- Earning Date
- VKTX 07-23-2025
- RNA 08-08-2025
- Dividend Yield
- VKTX N/A
- RNA N/A
- EPS Growth
- VKTX N/A
- RNA N/A
- EPS
- VKTX N/A
- RNA N/A
- Revenue
- VKTX N/A
- RNA $8,927,000.00
- Revenue This Year
- VKTX N/A
- RNA N/A
- Revenue Next Year
- VKTX N/A
- RNA $196.18
- P/E Ratio
- VKTX N/A
- RNA N/A
- Revenue Growth
- VKTX N/A
- RNA N/A
- 52 Week Low
- VKTX $18.92
- RNA $21.51
- 52 Week High
- VKTX $81.73
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- VKTX 73.08
- RNA 67.36
- Support Level
- VKTX $31.22
- RNA $33.02
- Resistance Level
- VKTX $33.61
- RNA $34.51
- Average True Range (ATR)
- VKTX 1.77
- RNA 2.00
- MACD
- VKTX 0.32
- RNA 0.39
- Stochastic Oscillator
- VKTX 89.49
- RNA 84.94
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.